News

Review: Opioid prescriptions are the work of many physicians


 

FROM JAMA INTERNAL MEDICINE

References

A “broad swath” of Medicare providers wrote scripts for opioids in 2013, contradicting the idea that the overdose epidemic is mainly the work of “small groups of prolific prescribers and corrupt pill mills,” investigators wrote online in JAMA Internal Medicine.

“Contrary to the California workers’ compensation data showing a small subset of prescribers accounting for a disproportionately large percentage of opioid prescribing, Medicare opioid prescribing is distributed across many prescribers and is, if anything, less skewed than all drug prescribing,” said Dr. Jonathan H. Chen of the Veterans Affairs Palo Alto (Calif.) Health Care System, and his associates.

Their study included 808,020 prescribers and almost 1.2 billion Medicare Part D claims worth nearly $81 billion dollars. They focused on schedule II opioid prescriptions containing oxycodone, fentanyl, hydrocodone, morphine, methadone, hydromorphone, oxymorphone, meperidine, codeine, opium, or levorphanol (JAMA Intern Med. 2015 Dec 14. doi: 10.1001/jamainternmed.2015.6662).

Not surprisingly, specialists in pain management, anesthesia, and physical medicine wrote the most prescriptions per provider. But family practitioners, internists, nurse practitioners, and physician assistants wrote 35,268,234 prescriptions – more than all other specialties combined. “The trends hold up across state lines, with negligible geographic variability,” the researchers said.

The findings contradict an analysis of California workers’ compensation data, in which 1% of prescribers accounted for a third of schedule II opioid prescriptions, and 10% of prescribers accounted for 80% of prescriptions, the investigators noted. Nonetheless, 10% of Medicare prescribers in Dr. Chen’s study accounted for 78% of the total cost of opioids, possibly because they were prescribing pricier formulations or higher doses.

Overall, the findings suggest that opioid prescribing is “widespread” and “relatively indifferent to individual physicians, specialty, or region” – and that efforts to stem the tide must be equally broad, the researchers concluded.

Their study was supported by the VA Office of Academic Affiliations, the VA Health Services Research and Development Service, the National Institute of General Medical Sciences, and the Peter F. McManus Charitable Trust. The researchers had no disclosures.

Recommended Reading

More than 75% with sickle cell crises don’t get hydroxyurea
MDedge Hematology and Oncology
ICOO: Opioid self-dosing falls short of pain control
MDedge Hematology and Oncology
ICOO: Massachusetts governor takes on opioid epidemic
MDedge Hematology and Oncology
ICOO: Quality metrics needed for medical marijuana
MDedge Hematology and Oncology
Only moderate-quality evidence supports medical cannabinoids
MDedge Hematology and Oncology
PCPC: Avoid these traps when prescribing medical marijuana
MDedge Hematology and Oncology
Hydroxyurea boosts O2 saturations in children with sickle cell disease
MDedge Hematology and Oncology
VIDEO: Use fiduciary duty to set pain medication boundaries
MDedge Hematology and Oncology
VIDEO: Consistency is key to monitoring patients on opioids
MDedge Hematology and Oncology
California governor signs physician-assisted suicide bill into law
MDedge Hematology and Oncology